Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Chemotherapy induces myeloid-driven spatial T-cell exhaustion in ovarian cancer.

Autor: Launonen IM; Research Program in Systems Oncology, University of Helsinki, Helsinki, Finland., Erkan EP; Research Program in Systems Oncology, University of Helsinki, Helsinki, Finland., Niemiec I; Research Program in Systems Oncology, University of Helsinki, Helsinki, Finland., Junquera A; Research Program in Systems Oncology, University of Helsinki, Helsinki, Finland., Hincapié-Otero M; Research Program in Systems Oncology, University of Helsinki, Helsinki, Finland., Afenteva D; Research Program in Systems Oncology, University of Helsinki, Helsinki, Finland., Liang Z; Research Program in Systems Oncology, University of Helsinki, Helsinki, Finland., Salko M; Research Program in Systems Oncology, University of Helsinki, Helsinki, Finland., Szabo A; Research Program in Systems Oncology, University of Helsinki, Helsinki, Finland., Perez-Villatoro F; Research Program in Systems Oncology, University of Helsinki, Helsinki, Finland., Falco MM; Research Program in Systems Oncology, University of Helsinki, Helsinki, Finland., Li Y; Research Program in Systems Oncology, University of Helsinki, Helsinki, Finland., Micoli G; Research Program in Systems Oncology, University of Helsinki, Helsinki, Finland., Nagaraj A; Research Program in Systems Oncology, University of Helsinki, Helsinki, Finland., Haltia UM; Research Program in Systems Oncology, University of Helsinki, Helsinki, Finland.; Department of Obstetrics and Gynecology, Department of Oncology, Clinical trials unit, Comprehensive Cancer Center, Helsinki University Hospital, Helsinki, Finland., Kahelin E; Research Program in Systems Oncology, University of Helsinki, Helsinki, Finland.; Department of Pathology, University of Helsinki and HUS Diagnostic Center, Helsinki University Hospital., Oikkonen J; Research Program in Systems Oncology, University of Helsinki, Helsinki, Finland., Hynninen J; Department of Obstetrics and Gynecology, University of Turku and Turku University Hospital, Turku, Finland., Virtanen A; Research Program in Systems Oncology, University of Helsinki, Helsinki, Finland.; Department of Pathology, University of Helsinki and HUS Diagnostic Center, Helsinki University Hospital., Nirmal AJ; Laboratory of Systems Pharmacology, Harvard Medical School, Boston, USA., Vallius T; Laboratory of Systems Pharmacology, Harvard Medical School, Boston, USA.; Ludwig Center at Harvard., Hautaniemi S; Research Program in Systems Oncology, University of Helsinki, Helsinki, Finland., Sorger P; Laboratory of Systems Pharmacology, Harvard Medical School, Boston, USA., Vähärautio A; Research Program in Systems Oncology, University of Helsinki, Helsinki, Finland.; Foundation for the Finnish Cancer Institute, Finland., Färkkilä A; Research Program in Systems Oncology, University of Helsinki, Helsinki, Finland.; Department of Obstetrics and Gynecology, Department of Oncology, Clinical trials unit, Comprehensive Cancer Center, Helsinki University Hospital, Helsinki, Finland.; iCAN Digital Precision Cancer Medicine Flagship, Helsinki, Finland.; Institute for Molecular Medicine Finland, Helsinki Institute for Life Sciences, University of Helsinki, Finland.

Publikováno v: BioRxiv : the preprint server for biology [bioRxiv] 2024 Mar 20. Date of Electronic Publication: 2024 Mar 20.